In a Phase I trial using escalating doses of Paclitaxel (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions myelosuppresstion was more profound when Paclitaxel was given after cisplatin than with the alternate sequence (i.e. Paclitaxel before cisplatin). Pharmacokinetic data from these patients demonstrated in Paclitaxel clearance of approximately 33% when Paclitaxel was administered following cisplatin. Based in in vitro data, there is the possibility of an inhibition of Paclitaxel metabolism in patients treated with ketoconazole. As a result, caution should be exercised when treating patients with Intaxel when they are receiving ketoconazole as concomitant therapy.
Sign Out
